Zealand Pharma’s shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.
https://whbl.com/2026/06/08/zealand-pharma-shares-drop-20-as-obesity-drug-side-effects-raise-concerns/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.